Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis

Clinical Biochemistry

Volumn 38, Issue 1, 2005, Pages 66-72

  Gur, Ali ^a   Colpan, Leyla ^a   Cevik, Remzi ^a   Nas, Kemal ^a   Jale Sarac, Aysegul ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Alendronate; Calcitonin; N telopeptide; Osteocalcin; Osteoporosis; Postmenopausal women; Zinc excretion

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CALCITONIN; CALCIUM; COLLAGEN TYPE 1; OSTEOCALCIN; PLACEBO; ZINC;

ADULT; AGED; ARTICLE; BONE REMODELING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ALENDRONATE; BIOLOGICAL MARKERS; BONE AND BONES; CALCITONIN; FEMALE; HUMANS; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; ZINC;

EID: 10644224266     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2004.10.001     Document Type: Article

References (31)

1. R.H. Christenson Biochemical markers of bone metabolism: an overview Clin. Biochem. 30 8 1997 573 593
2. J. Eaton-Evans Osteoporosis and the role of diet Br. J. Biomed. Sci. 51 4 1994 358 370
3. G. Howard, M. Andon, M. Bracker, P. Saltman, and L. Strause Low serum copper, a risk factor additional to low dietary calcium in postmenopausal bone loss J. Trace Elem. Exp. Med. 5 1992 23 31
4. O. Itan, and R.C. Tsang Bone disease L.A. Kaplan A.J. Desce Clinical chemistry. Theory, analysis, and correlation third ed. 1996 Mosby London 528 554
5. N.R. Calhoun, J.C. Smith, and K.L. Becker The role of zinc in bone metabolism Orthopedics 103 1974 212 234
6. S. Kishi, Y. Segawa, and M. Yamaguchi Histomorphological confirmation of the preventive effect of beta-alanyl-l-histidinato zinc on bone loss in ovariectomized rats Biol. Pharm. Bull. 17 6 1994 862 865
7. M. Yamaguchi, and S. Kishi Prolonged administration of beta-alanyl-l-histidinato zinc prevents bone loss in on the deterioration ovariectomized rats Jpn. J. Biopharmacol. 63 2 1993 203 207
8. A. Gur, L. Colpan, and K. Nasa The role of trace minerals in the pathogenesis of postmenopausal osteoporosis and a new effect of calcitonin J. Bone Miner. Metab. 20 2002 39 43
9. R. Eastell, S.P. Robins, and T. Colwell Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption Osteoporos. Int. 3 1993 255 260
10. P. Garnero, W.J. Shih, E. Gineyts, D.B. Karpf, and P.D. Delmas Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment J. Clin. Endocrinol. Metab. 79 1994 1693 1700
11. L.G. Raisz, B. Wiita, and A. Artis Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women J. Clin. Endocrinol. Metab. 81 1996 37 43
12. M.T. Parvainen, K. Jaaskelainen, H. Kröger, I. Arnala, and E. Alhava Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis Clin. Chim. Acta 279 1999 145 154
13. K. Overgaard, M.A. Hansen, and V.-A.H. Nielsen Discontinuous calcitonin treatment of established osteoporosis-Effects of withdrawal of treatment Am. J. Med. 89 1990 1 6
14. M. Herzbeg, J. Foldes, R. Steinberg, and J. Menczel Zinc excretion in osteoporotic women J. Bone Miner. Res. 5 1990 251 257
15. F. Brouns, and C. Vermeer Functional food ingredients for reducing the risks of osteoporosis Trends Food Sci. Technol. 11 2000 22 33
16. P. Relea, M. Revilla, and E. Ripoll Zinc biochemical markers of nutrition, and type 1 osteoporosis Age Ageing 24 1995 303 307
17. L. Steidl, and R. Ditmar Blood zinc findings in osteoporosis Acta Univ. Palacki. Olomuc., Fac. Med. 126 1990 129 138
18. S. Wallach Relation of magnesium to osteoporosis and calcium urolithiasis Magnes. Trace Elem. 10 1991-92 281 286
19. L. Steidl, R. Ditmar, and R. Kubicek Biochemical findings in osteoporosis: I. The significance of magnesium Cas. Leck. Cesk. 12 129 2 1990 51 55
20. A.L. Bunchman, C.L. Keen, and H.V. Vinters Copper deficiency secondary to a copper transport defect: a new copper metabolic disturbance Metabolism 43 12 1994 1462 1469
21. Colpan L, Gur A, Cevik R, Nas K, Sarac AJ. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis: a double-blind and placebo-controlled trial. Maturitas (in press).
22. J.J. Stepan, and J. Vokrouhlicka Comparison of biochemical markers of bone remodeling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis Clin. Chim. Acta 288 1999 121 135
23. C.H. Chesnut III, N.H. Bell, and G.S. Clark Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effects and predicts response of bone mineral density Am. J. Med. 102 1997 29 37
24. P. Garnero, C. Darte, and P.D. Delmas A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover Bone 24 1999 603 609
25. P. Ravn, D.E. Thompson, P.D. Ross, and C. Christiansen Biochemical markers for prediction of 4-year response in bone mass during bisphosphanate treatment for prevention of postmenopausal osteoporosis Bone 33 1 2003 150 158
26. K.E. Ensrud, D.M. Black, and L. Palermo Treatment with alendronate prevents fractures in women at highest risk: results from the fracture intervention trial Arch. Intern. Med. 157 22 1997 2617 2624
27. O. Chaki, I. Yoshikata, and R. Kikuchi The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women J. Bone Miner. Res. 15 8 2000 1537 1544
28. D.C. Bauer, P.M. Sklarin, and K.L. Stone Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures J. Bone Miner. Res. 14 1999 1404 1410
29. M.A. Garcia-Perez, J. Moreno-Mercer, J.J. Tarin, and A. Cano Relationship between PTH, sex steroid and bone turnover marker measurements and bone density in recently postmenopausal women Maturitas 45 2003 67 74
30. S.L. Greenspan, H.N. Rosen, and R.A. Parker Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type I predict long-term response to alendronate therapy in elderly women J. Clin. Endocrinol. Metab. 85 2000 3537 3540
31. H.A.P. Pols, D. Felsenberg, and D. Hanley A multinational randomized trial of the effects of alendronate on bone mineral density and fracture risk in postmenopausal women with low bone mass: result of the FOSIT study Osteoporos. Int. 9 5 1999 461 468